指南与共识消化与肝胆胰病理细胞病理与分子病理

儿童横纹肌肉瘤报告数据集:ICCR推荐

Data set for reporting of paediatric rhabdomyosarcoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).
指南 / 共识 · Histopathology · 2025-02-25

国际癌症报告协作组织(ICCR)组织病理学家与儿童肿瘤学家制定首个儿童横纹肌肉瘤活检与切除标本报告数据集,包含核心与非核心要素,涵盖临床、大体、镜下及辅助检测,旨在标准化报告并支持全球数据比较。

要点

  • 儿童横纹肌肉瘤报告应整合组织学、免疫组化与分子数据。
  • 数据集分为核心与非核心要素,基于当前证据与临床试验需求选择。
  • 标准化报告有助于患者分层治疗、临床试验与癌症登记。

核心结论

  • 首个国际儿童横纹肌肉瘤报告数据集旨在促进标准化高质量报告,支持全球临床数据比较,最终改善患者结局。

研究设计与样本

  • 国际专家小组由病理学家和儿童肿瘤学家组成,基于当前证据回顾制定核心与非核心要素。

主要发现

  • 数据集涵盖临床、大体、镜下及辅助检测要素,每个要素附有选择理由与临床相关性 commentary。

关键数值与推荐

  • 数据要素选择基于患者治疗分层必需及临床试验中使用的项目。

临床怎么用

  • 病理报告应纳入核心要素,并按需纳入非核心要素,以支持治疗分层与临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Rhabdomyosarcoma (RMS) is rare, but it is the most common sarcoma in childhood. The World Health Organisation classifies RMS into four main categories, sharing the same terminology of RMS, but the subtypes have different morphology, clinical behaviour and underlying molecular characterisation. Although the main diagnostic categories have remained the same there have been changes in the histological criteria, together with integration of both immunohistochemical and molecular data in the reporting of RMS. Integrated histology reporting provides valuable information for the management of children with RMS, is important for patients enrolled into clinical trials, supports tissue-based biological research and contributes to data required in cancer registries. Consistent, comprehensive and reproducible reporting of RMS is imperative. METHODS AND RESULTS: In this article we provide the International Collaboration on Cancer Reporting (ICCR) process for the development of the first international Paediatric RMS data set for the reporting of biopsy and resection specimens. An international expert panel consisting of pathologists and paediatric oncologists produced a set of core and non-core elements to be included in the histopathology reporting of paediatric RMS, inclusive of clinical, macroscopic, microscopic and ancillary testing required for a comprehensive report. The selection of data items was based on review of current evidence, taking into account items that are recognised as essential for patient treatment stratification and that are currently in use in the clinical trial setting. Commentary was provided for each data item to detail the rationale for selecting it as core or non-core element, and to highlight their clinical relevance. CONCLUSIONS: The first international data set for the reporting of paediatric RMS aims to promote standardised, high-quality reporting and supports uniform data collection, which is critical for clinical data comparison on a global level, ultimately improving patient outcome.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Kelsey A, Alaggio R, Webster F, et al. Data set for reporting of paediatric rhabdomyosarcoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2025. PMID: 40007148. doi:10.1111/his.15431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。